Investor Relations

Investor Relations Portal

Corporate Profile

Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use. The company’s lead FDA approved commercial product, NUZYRA® (omadacycline) is a once-daily intravenous and oral antibiotic for the treatment of adult patients with CABP and ABSSSI caused by susceptible pathogens.

Paratek has entered into a collaboration agreement with Zai Lab for the development and commercialization of omadacycline in the greater China region and retains all remaining global rights.

Under a broad-based Project BioShield contract with  Biomedical Advanced Research and Development Authority, or BARDA,  which is  a  part  of  the  United States Department of Health and Human Services and the Office of the Assistant Secretary for Preparedness and Response, NUZYRA® is being studied against anthrax, a pathogenic agent that potentially causes an infectious disease of public health and biodefense importance.

Paratek’s second FDA approved commercial product, SEYSARA®(sarecycline), is marketed by Almirall, LLC in the U.S. as a new once-daily oral therapy for the treatment of moderate to severe acne vulgaris. Paratek also granted a license to Almirall for SEYSARA in the greater China region, which includes the Peoples Republic of China, Hong Kong, and Macau. Almirall plans to develop sarecycline for acne in China, with a submission to the China National Medical Products Administration expected in 2023. Paratek retains development and commercialization rights to sarecycline in the rest of the world.

Recognizing the serious threat of bacterial infections, Paratek is dedicated to providing solutions that enable positive outcomes and lead to better patient stories.

Recent Press

View All
PRTK (Common Stock)
Detailed Charts
Upcoming Events
No events currently scheduled
Most Recent Corporate Presentation

May 4, 2022

Most Recent Corporate Presentation (May 2022)

August 11, 2021

Paratek Pharmaceuticals to Present at Wedbush PacGrow Healthcare Conference 2021

August 9, 2021

Paratek Pharmaceuticals Q2 2021 Earnings Conference Call

June 16, 2021

Paratek Pharmaceuticals Corporate Update and Key Opinion Leader and Patient Advocate Presentations on Non-Tuberculous Mycobacteria, M. abscessus Webinar

May 17, 2021

Paratek Pharmaceuticals Q1 2021 Earnings Conference Call

February 24, 2021

Paratek Pharmaceuticals Q4 2020 Earnings Conference Call